Threatened equity: Regional asymmetries in drug investments in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/20896 |
Resumo: | The health systems of the countries are suffering an increase in their expenses, for several reasons in Brazil, it is not different. From 2006 to 2013, investments in drug procurements by the Federal Government increased by 172%. Despite the achievements with the SUS, access to medicines is still not easy in several Brazilian regions. This work aims to analyze investments in medicines made by the Union, states and municipalities between 2010 and 2019 in order to identify regional differences in the application of these financial resources. It was observed that although the per capita investments in health were higher by the municipalities (R$ 926.54), when it comes to medicines, this per capita investment is higher by the Union (R$ 61.89). It was also identified that municipalities in the Northeast and North regions invest less in the procurement of medicines when compared to the national average (R$ 40.41), R$ 24.20 and R$ 23.58 respectively. When exploring the percentage of investment in medicine compared to the total investment in health among entities, it is possible to verify that states and municipalities have been decreasing their percentage of investment in medicines, highlighting the largest reduction made by the states (72.8% during the period analyzed). When the vulnerability indicator is used, it appears that the greater is the social vulnerability of the municipality, the lower are the amounts invested in medicines. The data show that the supply of medicines may be adversely affected in the main care entities (municipalities), especially in regions with a higher degree of social vulnerability. It is observed precisely where the support of the public health service is most dependent. |
id |
UNIFEI_7d45cb837552e5326561c3b9488e40a3 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/20896 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Threatened equity: Regional asymmetries in drug investments in BrazilEquidad amenazada: asimetrías regionales en inversiones en medicamentos en BrasilEquidade ameaçada: Assimetrias regionais nos investimentos em medicamentos no BrasilInvestimento em saúdeServiços de Assistência FarmacêuticaCustos de MedicamentosPolítica Nacional de Assistência Farmacêutica.Inversiones en SaludServicios FarmacéuticosCostos de los MedicamentosPolítica Nacional de Asistencia Farmacéutica.InvestmentsPharmaceutical ServicesDrug CostsNational Policy of Pharmaceutical Assistance.The health systems of the countries are suffering an increase in their expenses, for several reasons in Brazil, it is not different. From 2006 to 2013, investments in drug procurements by the Federal Government increased by 172%. Despite the achievements with the SUS, access to medicines is still not easy in several Brazilian regions. This work aims to analyze investments in medicines made by the Union, states and municipalities between 2010 and 2019 in order to identify regional differences in the application of these financial resources. It was observed that although the per capita investments in health were higher by the municipalities (R$ 926.54), when it comes to medicines, this per capita investment is higher by the Union (R$ 61.89). It was also identified that municipalities in the Northeast and North regions invest less in the procurement of medicines when compared to the national average (R$ 40.41), R$ 24.20 and R$ 23.58 respectively. When exploring the percentage of investment in medicine compared to the total investment in health among entities, it is possible to verify that states and municipalities have been decreasing their percentage of investment in medicines, highlighting the largest reduction made by the states (72.8% during the period analyzed). When the vulnerability indicator is used, it appears that the greater is the social vulnerability of the municipality, the lower are the amounts invested in medicines. The data show that the supply of medicines may be adversely affected in the main care entities (municipalities), especially in regions with a higher degree of social vulnerability. It is observed precisely where the support of the public health service is most dependent.Los sistemas de salud de los países están sufriendo un aumento en sus gastos, por varias razones, en Brasil no es diferente. De 2006 a 2013, las inversiones en compra de medicamentos por parte del Gobierno Federal aumentaron un 172%. A pesar de los logros alcanzados con el SUS, el acceso a los medicamentos aún no es fácil en varias regiones brasileñas. En este trabajo se realizó un análisis de las inversiones en medicamentos por parte de la Unión, estados y municipios entre 2010 y 2019, con el objetivo de identificar diferencias regionales en la aplicación de estos recursos. Se observó que si bien las inversiones per cápita en salud fueron mayores por parte de los municipios (R$ 926,54), en lo que respecta a medicamentos, esta inversión per cápita es mayor por parte de la Unión (R$ 61,89). También se identificó que los municipios de las regiones Nordeste y Norte invierten menos en la compra de medicamentos en comparación con el promedio nacional (R$ 40,41), R$ 24,20 y R$ 23,58 respectivamente. Al explorar el porcentaje de inversión en medicina frente a la inversión total en salud entre entidades, se puede constatar que los estados y municipios han venido disminuyendo su porcentaje de inversión en medicamentos, destacando la mayor reducción por estados (72,8% durante el período evaluado). Cuando se utiliza el indicador de vulnerabilidad, parece que cuanto mayor es la vulnerabilidad social del municipio, menores son los montos invertidos en medicamentos. Los datos muestran que las principales entidades asistenciales (municipios) pueden verse comprometidas en el suministro de medicamentos, y especialmente en regiones con mayor grado de vulnerabilidad social, precisamente donde el apoyo del servicio público de salud es más dependiente.Os sistemas de saúde dos países estão sofrendo aumento nos seus gastos, por vários motivos, no Brasil não é diferente. De 2006 a 2013 os investimentos com compras de medicamentos pelo Governo Federal aumentaram 172%. Apesar das conquistas alcançadas com o SUS, o acesso a medicamentos ainda não é fácil em várias regiões brasileiras. Nesse trabalho foi realizada a análise dos investimentos em medicamentos pela União, estados e municípios entre 2010 e 2019, objetivando identificar as diferenças regionais na aplicação desses recursos. Observou-se que apesar dos investimentos per capta em saúde ter sido maior pelos municípios (R$ 926,54), quando se trata de medicamentos esse investimento per capta é maior pela União (R$ 61,89). Identificou-se também que os municípios das regiões Nordeste e Norte investem menos na aquisição de medicamentos quando comparado com a média nacional (R$ 40,41), R$ 24,20 e R$ 23,58 respectivamente. Ao explorar o percentual de investimento em medicamento frente ao investimento total em saúde entre os entes, é possível verificar que estados e municípios vêm diminuindo seus percentuais de investimento em medicamentos, destacando-se a maior redução pelos estados (72,8% durante o período avaliado). Quando utilizado indicador de vulnerabilidade, consta-se que quanto maior a vulnerabilidade social do município, menores são os valores investidos em medicamentos. Os dados demonstram que pode haver comprometimento na execução da oferta de medicamentos pelos principais entes assistenciais (municípios) e especialmente nas regiões com maior grau de vulnerabilidade social, justamente onde mais se depende do apoio do serviço público de saúde.Research, Society and Development2021-10-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2089610.33448/rsd-v10i13.20896Research, Society and Development; Vol. 10 No. 13; e179101320896Research, Society and Development; Vol. 10 Núm. 13; e179101320896Research, Society and Development; v. 10 n. 13; e1791013208962525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/20896/19195Copyright (c) 2021 Wendell Rodrigues Oliveira da Silva; Rafael Santos Santana; Anna Maly de Leão e Neves Eduardo; Rayssa Samara Ferreira Martins; Silvana Nair Leitehttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Wendell Rodrigues Oliveira da Santana, Rafael Santos Eduardo, Anna Maly de Leão e Neves Martins, Rayssa Samara Ferreira Leite, Silvana Nair 2021-11-21T18:26:28Zoai:ojs.pkp.sfu.ca:article/20896Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:40:24.814562Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Threatened equity: Regional asymmetries in drug investments in Brazil Equidad amenazada: asimetrías regionales en inversiones en medicamentos en Brasil Equidade ameaçada: Assimetrias regionais nos investimentos em medicamentos no Brasil |
title |
Threatened equity: Regional asymmetries in drug investments in Brazil |
spellingShingle |
Threatened equity: Regional asymmetries in drug investments in Brazil Silva, Wendell Rodrigues Oliveira da Investimento em saúde Serviços de Assistência Farmacêutica Custos de Medicamentos Política Nacional de Assistência Farmacêutica. Inversiones en Salud Servicios Farmacéuticos Costos de los Medicamentos Política Nacional de Asistencia Farmacéutica. Investments Pharmaceutical Services Drug Costs National Policy of Pharmaceutical Assistance. |
title_short |
Threatened equity: Regional asymmetries in drug investments in Brazil |
title_full |
Threatened equity: Regional asymmetries in drug investments in Brazil |
title_fullStr |
Threatened equity: Regional asymmetries in drug investments in Brazil |
title_full_unstemmed |
Threatened equity: Regional asymmetries in drug investments in Brazil |
title_sort |
Threatened equity: Regional asymmetries in drug investments in Brazil |
author |
Silva, Wendell Rodrigues Oliveira da |
author_facet |
Silva, Wendell Rodrigues Oliveira da Santana, Rafael Santos Eduardo, Anna Maly de Leão e Neves Martins, Rayssa Samara Ferreira Leite, Silvana Nair |
author_role |
author |
author2 |
Santana, Rafael Santos Eduardo, Anna Maly de Leão e Neves Martins, Rayssa Samara Ferreira Leite, Silvana Nair |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Silva, Wendell Rodrigues Oliveira da Santana, Rafael Santos Eduardo, Anna Maly de Leão e Neves Martins, Rayssa Samara Ferreira Leite, Silvana Nair |
dc.subject.por.fl_str_mv |
Investimento em saúde Serviços de Assistência Farmacêutica Custos de Medicamentos Política Nacional de Assistência Farmacêutica. Inversiones en Salud Servicios Farmacéuticos Costos de los Medicamentos Política Nacional de Asistencia Farmacéutica. Investments Pharmaceutical Services Drug Costs National Policy of Pharmaceutical Assistance. |
topic |
Investimento em saúde Serviços de Assistência Farmacêutica Custos de Medicamentos Política Nacional de Assistência Farmacêutica. Inversiones en Salud Servicios Farmacéuticos Costos de los Medicamentos Política Nacional de Asistencia Farmacéutica. Investments Pharmaceutical Services Drug Costs National Policy of Pharmaceutical Assistance. |
description |
The health systems of the countries are suffering an increase in their expenses, for several reasons in Brazil, it is not different. From 2006 to 2013, investments in drug procurements by the Federal Government increased by 172%. Despite the achievements with the SUS, access to medicines is still not easy in several Brazilian regions. This work aims to analyze investments in medicines made by the Union, states and municipalities between 2010 and 2019 in order to identify regional differences in the application of these financial resources. It was observed that although the per capita investments in health were higher by the municipalities (R$ 926.54), when it comes to medicines, this per capita investment is higher by the Union (R$ 61.89). It was also identified that municipalities in the Northeast and North regions invest less in the procurement of medicines when compared to the national average (R$ 40.41), R$ 24.20 and R$ 23.58 respectively. When exploring the percentage of investment in medicine compared to the total investment in health among entities, it is possible to verify that states and municipalities have been decreasing their percentage of investment in medicines, highlighting the largest reduction made by the states (72.8% during the period analyzed). When the vulnerability indicator is used, it appears that the greater is the social vulnerability of the municipality, the lower are the amounts invested in medicines. The data show that the supply of medicines may be adversely affected in the main care entities (municipalities), especially in regions with a higher degree of social vulnerability. It is observed precisely where the support of the public health service is most dependent. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-10-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/20896 10.33448/rsd-v10i13.20896 |
url |
https://rsdjournal.org/index.php/rsd/article/view/20896 |
identifier_str_mv |
10.33448/rsd-v10i13.20896 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/20896/19195 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 13; e179101320896 Research, Society and Development; Vol. 10 Núm. 13; e179101320896 Research, Society and Development; v. 10 n. 13; e179101320896 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052833928839168 |